Drug Search Results
More Filters [+]

Tirabrutinib

Alternative Names: tirabrutinib, ono-4059, gs-4059, ono4059, gs4059
Latest Update: 2024-04-22
Latest Update Note: PubMed Publication

Product Description

Tirabrutinib (Velexbru¨) is an orally administered, small molecule, Bruton's tyrosine kinase (BTK) inhibitor being developed by Ono Pharmaceutical and its licensee Gilead Sciences for the treatment of autoimmune disorders and haematological malignancies. Tirabrutinib irreversibly and covalently binds to BTK in B cells and inhibits aberrant B cell receptor signalling in B cell-related cancers and autoimmune diseases. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32382949/)

Mechanisms of Action: Btk Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Orphan Drug - Lymphoma|Primary Central Nervous System Lymphoma *

Approval Status: Not Approved

Approved Countries: Japan | Taiwan

Approved Indications: None

Known Adverse Events: None

Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additonal Commercial Interests: Gilead Sciences

Clinical Description

Map of Global Clinical Trials for Tirabrutinib

Countries in Clinic: Japan, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Pemphigus

Phase 2: Chronic Lymphoid Leukemia|Primary Central Nervous System Lymphoma

Phase 1: Scleroderma, General

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

jRCT2071230124

P1

Not yet recruiting

Primary Central Nervous System Lymphoma

2028-03-31

jRCT2031200315

P1

Active, not recruiting

Scleroderma, General

2027-10-31

PROSPECT Study

P2

Recruiting

Primary Central Nervous System Lymphoma

2027-03-31

57%

jRCT2031220043

P3

Suspended

Pemphigus

2026-12-31

Recent News Events